EXAS News

Latest breaking news and updates for EXAS stock.

Track all markets on TradingView

Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.

Could this legal outcome trigger any strategic moves or partnerships within the colorectal diagnostics sector? What potential market share gains could Geneoscopy achieve if the 781 and 746 patents are upheld? How will the withdrawal of the preliminary injunction affect Geneoscopy's short‑term stock momentum?
Lawsuits
5 days ago
Read more businesswire

Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer

– Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones – – Final module for the first version of Freenome's colorectal cancer test has been su...

How sensitive is the deal’s financial upside to macro‑economic factors or changes in healthcare policy? What impact could the launch have on Exact Sciences' existing product portfolio and sales focus? Are there any contingent earn‑out clauses or performance targets that could accelerate or defer payments under the agreement?
Deal
21 days ago
Read more prnewswire

Exact Sciences Announces Second Quarter 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million ...

Is there any insider buying or selling activity around the release that might signal management sentiment? How is the market pricing the latest earnings surprise, and are short‑term trading opportunities emerging from the news? What are the implications of the increased patient volume for market share and long‑term revenue trajectory?
Earnings
21 days ago
Read more businesswire

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer de...

How is the market likely to price in this partnership given the 70 sentiment rating and the broader industry trend toward liquid biopsy solutions? What is the expected impact on cash flow, operating expenses, and capital allocation for Exact Sciences? Are there potential follow‑on collaborations or acquisitions with Freenome or other early detection platforms?
Partnership
21 days ago
Read more businesswire